The Briefing
- On June 9, 2026, the FDA approved bemotrizinol (BEMT) — the first UV filter added to the U.S. over-the-counter sunscreen monograph since 1999 — with product sales permitted starting August 9.
- Already trusted in Europe since 2000, BEMT offers broad-spectrum coverage in a single ingredient, degrades far more slowly under sunlight than most legacy U.S. filters, and leaves no white cast on any skin tone.
- Ultra Violette launched the first U.S. BEMT product on August 31, 2026; Neutrogena followed on September 17 as the first American drugstore brand, with a broader wave of reformulations expected through 2027.
American sunscreen shoppers have spent the past quarter-century choosing from the same fixed roster of UV filters every time they picked up a bottle. That era ended this fall. After the FDA approved bemotrizinol — also called BEMT — on June 9, 2026, as the first ingredient added to the over-the-counter sunscreen monograph since 1999, brands moved quickly toward commercialization. Within weeks, the first products were already reaching U.S. consumers online, and the broader market was preparing to follow.
A Quarter-Century Without a New Filter
The regulatory gap that BEMT closes stretches back to when satellite phones were a luxury and broadband internet had not yet reached most American homes. While regulators in Europe, Australia, and much of Asia approved dozens of new UV filters over the following decades, the United States treated sunscreen as an over-the-counter drug rather than the cosmetic designation used across the European Union — a classification that made the American approval process substantially slower than those of its international counterparts. BEMT had been in widespread commercial use across Europe since 2000, accumulating more than two decades of real-world safety data while American consumers had no domestic path to access it.
The logjam began to crack when Congress passed the Coronavirus Aid, Relief, and Economic Security Act in 2020, which established a streamlined administrative order process for updating over-the-counter drug monographs. Under that reformed pathway, DSM-Firmenich — the Swiss-Dutch ingredient supplier that spent more than two decades and at least $18 million pursuing U.S. regulatory clearance — submitted a formal monograph order request. The FDA issued a proposed order on December 12, 2025, accepted public comments through January 26, 2026, and issued its final administrative order within approximately seven months, a pace that demonstrated what the reformed process could accomplish when applied to a well-documented ingredient.
What Sets BEMT Apart From Existing Options
Bemotrizinol is a broad-spectrum chemical filter — one ingredient that handles both UVA and UVB rays without requiring manufacturers to blend several separate compounds to achieve full-spectrum coverage. That distinction matters because the principal non-mineral UVA option currently available in U.S. formulas, avobenzone, is prone to photodegradation — it breaks down under direct sunlight at a rate that reduces its effectiveness during a day outdoors. BEMT is highly photostable, resisting that breakdown far more effectively — a property that translates into more consistent protection during extended sun exposure.
Why Deeper Skin Tones Stand to Benefit Most
Among the most persistent barriers to daily sunscreen use — particularly among people with medium to deep skin tones — has been the chalky white residue that mineral formulas containing zinc oxide leave behind. Chemical filters sidestep that problem in principle, but older options have drawn scrutiny over how readily they absorb into the bloodstream. BEMT occupies a different category: because its molecules are larger than those of most legacy chemical filters, the ingredient stays predominantly on the skin's surface rather than penetrating into the body. The FDA has classified it as generally recognized as safe and effective for adults and children as young as six months old — an age threshold that extends younger than most currently approved chemical UV filters in the United States.
Beyond the absorption science, dermatologists note that BEMT blends cleanly into the skin, leaves no visible white film, and carries a lighter sensory profile than many existing options. Researchers and clinicians widely argue that sunscreen's texture and finish are among the primary reasons daily compliance rates remain low — making the wearability of a formula a direct factor in public health outcomes, not simply a cosmetic preference.
Two Early Launches Signal What Is Coming
The first commercial BEMT product to reach U.S. consumers came from an overseas label. Ultra Violette, an Australian sunscreen brand, launched its Unblock Screen SPF 50 at Sephora on August 31, 2026 — just weeks after the FDA's final order took effect. Neutrogena became the first major American drugstore brand to follow, listing two facial formulas on Amazon on September 17, 2026: the Ultra Sheer Daily Face Sunscreen SPF 70 and the Clear Face Sunscreen SPF 60. Both products combine BEMT with the brand's Helioplex360 UV-filter technology under what Neutrogena calls its Cloud-Tech formulation — engineered for a texture the company describes as roughly 50 percent lighter on skin than its prior non-BEMT comparable formula. The Clear Face version incorporates niacinamide and vitamin E to address acne-prone skin. Broader in-store retail distribution for both products was expected to follow in October 2026.
According to Dermatology Times, those launches represent the early edge of a much larger wave of reformulations anticipated through the rest of 2026 and into 2027, as competing brands work through the manufacturing, labeling, and drug-listing requirements for incorporating the new ingredient into OTC sunscreen products.
One Supplier Controls Access — For Now
For the next year and a half, the market runs through a single source. Consumer Reports confirmed that DSM-Firmenich holds 18 months of exclusive U.S. marketing rights on BEMT, timed from the launch of the first commercial product. The company supplies the ingredient to sunscreen manufacturers under the brand name Parsol Shield. DSM-Firmenich — which first filed the ingredient with the FDA back in 2005 — has signaled its intention to monitor the exclusivity window closely and police the purity specifications built into the agency's final administrative order.
The Bigger Picture: Skin Cancer and Daily Protection
The broader stakes extend well beyond product variety. Skin cancer is the most commonly diagnosed cancer in the United States, and public health advocates have long maintained that sunscreen compliance is eroded partly by how available formulas look and feel on the skin. The American Academy of Dermatology Association called the approval "an important public health step" that expands access to effective protection and could contribute to reducing preventable skin cancer deaths. Dermatologists across multiple outlets echoed that perspective, arguing the formula's wearability advantages are not cosmetic luxuries but a meaningful lever for improving how consistently people actually use protection each day.
Clinicians are careful to frame sunscreen as one component in a broader protection strategy. Broad-spectrum products at SPF 30 or higher, reapplied every two hours, work best alongside UV-protective clothing, wide-brimmed hats, and deliberate shade. But with BEMT now available, American consumers finally have access to a filter the rest of the developed world had incorporated into everyday sun care for more than two decades.
© {{Year}} Latin Times. All rights reserved. Do not reproduce without permission.